Harmony Biosciences Holdings, Inc.

Harmony Biosciences is a commercial-stage neuroscience company focused on developing and commercializing therapies for patients living with rare neurological diseases. Its therapeutic portfolio spans sleep and wake disorders, rare epilepsies, and neurobehavioral conditions. The company's lead commercial product is WAKIX, a selective histamine 3 receptor antagonist/inverse agonist administered once daily for the treatment of excessive daytime sleepiness and cataplexy in adult and pediatric narcolepsy patients. Harmony also advances a clinical pipeline of next-generation pitolisant formulations, orexin receptor agonists, and serotonin receptor agonists. The company sells its commercial therapies to specialty pharmacies and distributors, including Caremark, Accredo Health Group, and PANTHERx Specialty Pharmacy, which supply patients.

The company operates through wholly owned subsidiaries and commercializes its core treatment in the United States, with licensed development and commercialization rights extending to Latin America for certain pipeline candidates. Harmony Biosciences does not own or operate manufacturing, storage, or distribution facilities, relying entirely on contracted third-party suppliers and manufacturers across the United States and Europe. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Harmony Biosciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 293 full-time employees, 135 dedicated to commercial functions, which includes sales, marketing, market access, commercial operations, and insights, and 103 dedicated to research and development.”